Two weeks after reporting that its lead drug failed a Phase II pain study, Aquinox Pharmaceuticals came back with more bad news this morning, noting its flop in a separate mid-stage study for chronic obstructive pulmonary disease patients with a history of frequent exacerbations.

…read more

Source: Back-to-back PhII flops for lead drug scuttles Aquinox stock


0 No comments